Japan’s Takeda Pharmaceutical will not be required to sell a biologic drug, a concession made to address EU antitrust concerns over its 2018 bid to buy Shire, because market conditions have changed, Reuters reported.
The European Commission announced it took the decision after an investigation was conducted following Takeda’s request to waive its pledge.
“On this basis, the Commission concluded that the combination of the above developments amounted to exceptional circumstances so that the divestment of SHP 647 was no longer necessary to render Takeda’s acquisition of Shire compatible with the internal market,” the EU competition enforcer said.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
